MENU
+Compare
APVO
Stock ticker: NASDAQ
AS OF
Feb 21 closing price
Price
$3.47
Change
+$0.06 (+1.76%)
Capitalization
5.06M

APVO Aptevo Therapeutics Inc Forecast, Technical & Fundamental Analysis

a provider of immunology and cancer research services

Industry Biotechnology
APVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for APVO with price predictions
Feb 18, 2025

APVO's RSI Indicator remains in oversold zone for 4 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where APVO advanced for three days, in of 215 cases, the price rose further within the following month. The odds of a continued upward trend are .

APVO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for APVO turned negative on February 14, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where APVO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for APVO entered a downward trend on February 18, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.064) is normal, around the industry mean (12.604). P/E Ratio (0.000) is within average values for comparable stocks, (85.387). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.581). APVO has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (0.000) is also within normal values, averaging (252.111).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. APVO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. APVO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
APVO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

APVO is expected to report earnings to fall 96.35% to -43 cents per share on May 09

Aptevo Therapeutics Inc APVO Stock Earnings Reports
Q1'24
Est.
$-0.44
Q4'23
Missed
by $11.52
Q3'23
Missed
by $21.36
Q2'23
Missed
by $53.00
Q1'23
Beat
by $1.61
The last earnings report on March 06 showed earnings per share of -1193 cents, missing the estimate of -40 cents. With 29.17K shares outstanding, the current market capitalization sits at 5.06M.
A.I. Advisor
published General Information

General Information

a provider of immunology and cancer research services

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
2401 4th Avenue
Phone
+1 206 838-0500
Employees
40
Web
https://www.aptevotherapeutics.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPY611.491.79
+0.29%
SPDR® S&P 500® ETF Trust
AAPL244.47-0.13
-0.05%
Apple
GME26.97-0.03
-0.11%
GameStop Corp
BTC.X95539.550000-233.835940
-0.24%
Bitcoin cryptocurrency
TSLA354.11-1.73
-0.49%
Tesla

APVO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, APVO has been loosely correlated with ATBPF. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if APVO jumps, then ATBPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APVO
1D Price
Change %
APVO100%
+4.49%
ATBPF - APVO
37%
Loosely correlated
N/A
ENLV - APVO
36%
Loosely correlated
N/A
KROS - APVO
29%
Poorly correlated
+2.33%
IBO - APVO
27%
Poorly correlated
-2.88%
ALLR - APVO
23%
Poorly correlated
+2.22%
More